Role of hepatitis B core-related antigen and antibodies to hepatitis B core antigen levels in the natural history of chronic HBV infection

2018 ◽  
Vol 50 (1) ◽  
pp. 12
Author(s):  
G.P. Caviglia ◽  
A. Olivero ◽  
A. Ciancio ◽  
F. Tandoi ◽  
G. Troshina ◽  
...  
Keyword(s):  
Natural History ◽  
Hepatitis B ◽  
Hbv Infection ◽  
Core Antigen ◽  
Chronic Hbv Infection ◽  
History Of ◽  
Chronic Hbv ◽  
Hepatitis B Core Antigen

Recombinant hepatitis B core antigen carrying preS1 epitopes induce immune response against chronic HBV infection

Vaccine ◽  
2004 ◽  
Vol 22 (3-4) ◽  
pp. 439-446 ◽  
Author(s):  
Xinchun Chen ◽  
Meizhong Li ◽  
Xiaohua Le ◽  
Weimin Ma ◽  
Boping Zhou
Keyword(s):  
Immune Response ◽  
Hepatitis B ◽  
Hbv Infection ◽  
Core Antigen ◽  
Recombinant Hepatitis ◽  
Chronic Hbv Infection ◽  
Chronic Hbv ◽  
Hepatitis B Core Antigen

scholarly journals Antiviral Activity and Pharmacokinetics of the HBV Capsid Assembly Modulator GLS4 in Patients with Chronic HBV Infection

2020 ◽  
Author(s):  
Hong Zhang ◽  
Fengjiao Wang ◽  
Xiaoxue Zhu ◽  
Yunfu Chen ◽  
Hong Chen ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Antiviral Activity ◽  
Accumulation Rate ◽  
Hbv Infection ◽  
Controlled Study ◽  
Core Antigen ◽  
Capsid Assembly ◽  
Chronic Hbv Infection ◽  
Chronic Hbv ◽  
The Mean

Abstract Background GLS4 is a first-in-class hepatitis B virus (HBV) capsid assembly modulator (class I) that can inhibit HBV replication by interfering with the assembly and disassembly of HBV nucleocapsid. Here, we evaluated its antiviral activity, pharmacokinetics (PK), and tolerability in a double-blind, randomized, parallel, entecavir-controlled study. Methods Twenty four chronic HBV patients were randomized to receive a 28-day course of GLS4 (120 or 240 mg) and ritonavir (100 mg) combination (cohorts A and B, respectively) or entecavir treatment (cohort C) at a 1:1:1 ratio. Patients were followed-up for 40 days in a phase 1b study. Results The GLS4/ritonavir combination was a tolerated combination for the treatment of chronic HBV infection. A total of two, three, and three subjects presented with alanine aminotransferase flare in cohorts A, B and C, respectively. This contributed to the withdrawal of one, two, and one patient from cohorts A, B and C, respectively. The mean Ctrough of GLS4 was 205–218 ng/mL, which was approximately 3.7–3.9 times the EC90 (55.8 ng/mL), with a lower accumulation (accumulation rate: 1.1–2.0). In cohorts A, B and C, the mean declines in HBV DNA after 28 days of treatment were -1.42, -2.13, and -3.5 log10 IU/mL; in hepatitis B surface antigen were -0.06, -0.14, and -0.33 log10 IU/mL; in pregenomic RNA were -0.75, -1.78, and -0.96 log10 copies/mL; and in hepatitis B core antigen (were -0.23, -0.5, and -0.44 log10 U/mL, respectively. Conclusions Treatment with 120 mg GLS4 was tolerated and had antiviral activity in patients with chronic HBV infection.

Revisiting the Natural History of Chronic HBV Infection

2016 ◽  
Vol 15 (3) ◽  
pp. 141-149 ◽  
Author(s):  
Hung-Chih Yang ◽  
Jia-Horng Kao
Keyword(s):  
Natural History ◽  
Hbv Infection ◽  
Chronic Hbv Infection ◽  
History Of ◽  
Chronic Hbv

Natural history of chronic HBV infection: A cohort study with up to 12 years follow-up in North Greece (part of the Interreg I-II/EC-project)

2005 ◽  
Vol 77 (2) ◽  
pp. 173-179 ◽  
Author(s):  
G.H. Zacharakis ◽  
J. Koskinas ◽  
S. Kotsiou ◽  
M. Papoutselis ◽  
F. Tzara ◽  
...  
Keyword(s):  
Cohort Study ◽  
Natural History ◽  
Hbv Infection ◽  
Chronic Hbv Infection ◽  
History Of ◽  
Chronic Hbv

scholarly journals The Immunologic Role of Gut Microbiota in Patients with Chronic HBV Infection

2018 ◽  
Vol 2018 ◽  
pp. 1-6 ◽  
Author(s):  
Ruilin Yang ◽  
Yao Xu ◽  
Zhifeng Dai ◽  
Xuhong Lin ◽  
Huichao Wang
Keyword(s):  
Hepatitis B ◽  
Gut Microbiota ◽  
Immune Modulation ◽  
Structural Changes ◽  
Hbv Infection ◽  
Chronic Liver Damage ◽  
Chronic Hbv Infection ◽  
Close Relationship ◽  
Chronic Hbv

Hepatitis B can cause acute or chronic liver damage due to hepatitis B virus (HBV) infection. Cirrhosis or hepatocellular carcinoma (HCC) caused by chronic HBV infection often leads to increased mortality. However, the gut and liver have the same embryonic origin; therefore, a close relationship must exist in terms of anatomy and function, and the gut microbiota plays an important role in host metabolic and immune modulation. It is believed that structural changes in the gut microbiota, bacterial translocation, and the resulting immune injury may affect the occurrence and development of liver inflammation caused by chronic HBV infection based on the in-depth cognition of the concept of the “gut-liver axis” and the progress in intestinal microecology. This review aims to summarize and discuss the immunologic role of the gut microbiota in chronic HBV infection.

Sign in / Sign up

Export Citation Format

Share Document